Browse by Poster Presenter

Skip to main content

ASCPT 2024 Annual Meeting Main banner

Browse by Poster Presenter

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Y
Yang, Derek

Pfizer, Inc.
PII-158 - THE EFFECT OF VEPDEGESTRANT, A PROTEOLYSIS TARGETING CHIMERA (PROTAC) ESTROGEN RECEPTOR (ER) DEGRADER, ON DABIGATRAN PHARMACOKINETICS (PK) IN HEALTHY ADULT PARTICIPANTS.
Derek Yang
Favorite
Yang, Eunsol

University of California, San Francisco
OAII-003 - A LONGITUDINAL HBA1C MODEL IN PATIENTS WITH TYPE 2 DIABETES ELUCIDATES THE ROLE OF CODING VARIANT IN GLUCOSE TRANSPORTER GENE, SLC2A2, ON GLYCEMIC RESPONSE TO METFORMIN.
Eunsol Yang
Favorite
PT-003 - A LONGITUDINAL HBA1C MODEL IN PATIENTS WITH TYPE 2 DIABETES ELUCIDATES THE ROLE OF CODING VARIANT IN GLUCOSE TRANSPORTER GENE, SLC2A2, ON GLYCEMIC RESPONSE TO METFORMIN.
Eunsol Yang
Favorite
Yang, Jianning

Astellas Pharma, Inc.
PII-066 - POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSES OF ZOLBETUXIMAB IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Jianning Yang
Favorite
Yan, Li

NGM Biopharmaceuticals
PII-144 - POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF NGM707, AN ILT2/ILT4 DUAL ANTAGONIST ANTIBODY IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS.
Li Yan
Favorite
PII-147 - POPULATION PHARMACOKINETIC MODELING OF NGM438 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS.
Li Yan
Favorite
Yoon, Deok Yong

Novartis
PT-020 - USE OF QUANTITATIVE MAGNETIC RESONANCE IMAGING BIOMARKERS IN CLINICAL TRIALS FOR DUCHENNE MUSCULAR DYSTROPHY: MULTIVARIATE DISEASE PROGRESSION MODELS BRIDGING TIMED MOTOR FUNCTION TESTS AND FAT FRACTION
Deok Yong Yoon
Favorite
PWI-003 - USE OF QUANTITATIVE MAGNETIC RESONANCE IMAGING BIOMARKERS IN CLINICAL TRIALS FOR DUCHENNE MUSCULAR DYSTROPHY: MULTIVARIATE DISEASE PROGRESSION MODELS BRIDGING TIMED MOTOR FUNCTION TESTS AND FAT FRACTION
Deok Yong Yoon
Favorite
Yuan, Jiajia

Peking University Cancer Hospital and Institute
PII-134 - PHARMACOKINETICS OF INFIGRATINIB AND ITS ACTIVE METABOLITES IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC CANCER OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA HARBORING FGFR2 GENE AMPLIFICATION
Jiajia Yuan
Favorite
Yu, Chongwoo

Division of Cardiometabolic and Endocrine Pharmacology, Office of Clinical Pharmacology, U.S. Food and Drug Administration
PII-191 - PEDIATRIC CLINICAL TRIAL DESIGNS FOR TESTOSTERONE REPLACEMENT THERAPY.
Chongwoo Yu
Favorite
Yue, Min

Purdue University
OAI-004 - ORAL PROGESTERONE-MEDIATED ATTENUATION OF IBUTILIDE-INDUCED QT INTERVAL LENGTHENING IN PREMENOPAUSAL AND POSTMENOPAUSAL WOMEN: POPULATION PHARMACOKINETIC/ PHARMACODYNAMIC MODEL
Min Yue
Favorite
PT-028 - ORAL PROGESTERONE-MEDIATED ATTENUATION OF IBUTILIDE-INDUCED QT INTERVAL LENGTHENING IN PREMENOPAUSAL AND POSTMENOPAUSAL WOMEN: POPULATION PHARMACOKINETIC/ PHARMACODYNAMIC MODEL
Min Yue
Favorite